CVS Health (CVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Charles Rhyee from TD Cowen upgraded the rating on the stock
CVS Health (CVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Charles Rhyee from TD Cowen upgraded the rating on the stock
Notable gainers among liquid option names this morning include Caesars (CZR) $42.94 +2.14, Walgreen Boots (WBA) $9.02 +0.32, Baker Hughes (BKR) $37.75 +1.00, CF Industries (CF) $89.50 +2.29, and CVS
Barclays says Humana (HUM) and Alignment Healthcare (ALHC) traded down yesterday amid Medicare Advantage star rating confusion. The selloffs were due to due to concerns around 2025 star ratings impacting
Morgan Stanley analyst Erin Wright maintained a Buy rating on CVS Health (CVS – Research Report) yesterday and set a price target of $65.00. Erin Wright’s rating is based on
Health insurers Cigna (CI), CVS Health (CVS), Humana (HUM), Centene (CNC) and UnitedHealth (UNH) released details on their government-backed health insurance plans for next year for people aged 65 and